Connable Office’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.91M Sell
4,240
-26
-0.6% -$30.7K 0.43% 33
2026
Q2
$5.12M Buy
4,266
+115
+3% +$118K 0.45% 32
2026
Q1
$3.82M Sell
4,151
-643
-13% -$652K 0.38% 36
2025
Q4
$5.15M Sell
4,794
-9
-0.2% -$8.61K 0.47% 31
2025
Q3
$3.66M Buy
4,803
+131
+3% +$97.5K 0.34% 37
2025
Q2
$3.64M Buy
4,672
+84
+2% +$65.3K 0.36% 33
2025
Q1
$3.79M Sell
4,588
-939
-17% -$781K 0.4% 33
2024
Q4
$4.27M Sell
5,527
-1,192
-18% -$987K 0.44% 37
2024
Q3
$5.95M Sell
6,719
-117
-2% -$105K 0.6% 27
2024
Q2
$6.19M Sell
6,836
-953
-12% -$762K 0.67% 24
2024
Q1
$6.06M Sell
7,789
-1,040
-12% -$740K 0.69% 25
2023
Q4
$5.15M Sell
8,829
-397
-4% -$232K 0.62% 27
2023
Q3
$4.96M Sell
9,226
-1,261
-12% -$650K 0.68% 25
2023
Q2
$4.92M Buy
10,487
+14
+0.1% +$5.87K 0.67% 25
2023
Q1
$3.6M Buy
10,473
+4,130
+65% +$1.39M 0.52% 28
2022
Q4
$2.32M Sell
6,343
-27
-0.4% -$9.6K 0.33% 58
2022
Q3
$2.06M Hold
6,370
– – 0.33% 56
2022
Q2
$2.06M Buy
+6,370
New +$1.91M 0.32% 58

Other funds holding LLY

Connable Office's LLY Position: Q3 2026 in Review

Connable Office reduced its Eli Lilly (LLY) stake by 0.61% in Q3 2026, selling an estimated $30.7K and leaving 4,240 shares worth $4.91M. The position accounts for 0.43% of the portfolio, ranked #33.

Connable Office first reported a position in LLY in Q2 2022 and has held it in 18 quarters since. The position peaked at $6.19M in Q2 2024. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Connable Office held 4,240 shares of Eli Lilly worth $4.91M as of Q3 2026.
  • Connable Office sold 26 Eli Lilly shares in Q3 2026, an estimated $30.7K.
  • Eli Lilly made up 0.43% of Connable Office's portfolio in Q3 2026, its #33 holding.
  • Connable Office first reported a position in Eli Lilly in Q2 2022 and has held it in 18 quarters since.
  • Connable Office's Eli Lilly position peaked at $6.19M in Q2 2024.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Connable Office's 13F filing for Q3 2026, filed 10 Nov 2026.